TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34348942
Drug: Peripherally acting
Normalized name: Peripherally acting antiobesity products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripherally acting mu-opioid receptor antagonist (PAMORA)
Study: 34348942
Drug: PAMORA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAMORA and conventional laxative
Study: 34348950
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy (MT) delivered in 10 sessions over 6 weeks with an accompanying home exercise programme (HEP)
Study: 34349026
Drug: CPL207280, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPL207280, a GPR40/FFA1 agonist; specific dosage and duration not mentioned
Study: 34349716
Drug: Arm Ergometry
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm Ergometry intervention, details on dosage and duration not available
Study: 34352165
Drug: Second-Generation Antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-Generation Antipsychotics
Study: 34352935
Drug: Poloxamer-based thermosensitive
Normalized name: Poloxamer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poloxamer-based thermosensitive sol-gel (PTAS) agent applied to the operative field after ALND
Study: 34353808
Drug: Cloxacillin 2
Normalized name: cloxacillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin 2 g/4-hour intravenous plus fosfomycin 3 g/6-hour intravenous for 7 days
Study: 34353808
Drug: Cloxacillin 2
Normalized name: cloxacillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin 2 g/4-hour intravenous alone for 7 days
Study: 34354225
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine (Rova-T) at 0.3 mg/kg every 6 weeks for two cycles
Study: 34354225
Drug: Rovalpituzumab tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine (Rova-T) at 0.3 mg/kg every 6 weeks
Study: 38062808
Drug: CAR T-cell
Normalized name: CD123-CD33cCAR T-cells
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR T-cell therapy
Study: 34355155
Drug: 16 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g/day of inulin (prebiotic) supplementation
Study: 34355741
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of gene alterations, number of metastatic sites, prior systemic therapies, presence of CTCs and PD-L1(+) CTCs
Study: 34355741
Drug: Squamous cell
Normalized name: Vespula squamosa venom protein
DrugBank: Vespula squamosa venom protein (DB11032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squamous cell carcinoma histology, number of prior systemic treatments, presence of CTC
Study: 34357561
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (once-daily)
Study: 34358484
Drug: Infigratinib 125
Normalized name: INFIGRATINIB 125 mg ORAL CAPSULE [TRUSELTIQ]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infigratinib 125 mg orally once daily for 21 days of 28-day cycles until disease progression, intolerance, withdrawal of consent, or death.
Study: 34359048
Drug: SIACI of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIACI of bevacizumab (15 mg/kg) and cetuximab (200 mg/m2)
Study: 34360156
Drug: COVID-19 vaccines
Normalized name: Covid-19 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccines (including booster doses)
Study: 34361902
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements and exercise training
Study: 34362494
Drug: C-CAR011 infusion
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-CAR011 infusion following lympho-depletion
Study: 34362494
Drug: C-CAR011 infusion
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-CAR011 infusion
Study: 34363393
Drug: Daily interactions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interactions
Study: 34363598
Drug: Current therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapy and clinical practices for PDN
Study: 34363598
Drug: Opium therapies
Normalized name: Opium
DrugBank: Opium (DB11130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opium therapies
Study: 34363598
Drug: Contradiction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contradiction of second-line guideline recommendation for opium dosage form
Study: 34363769
Drug: Parenteral low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral low-molecular-weight or unfractionated heparin for 72 hours followed by oral dabigatran 150 mg twice per day
Study: 34365644
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg (twice daily)
Study: 34365878
Drug: KA2237, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: KA2237, a dual p110β/p110δ inhibitor, administered orally.
Study: 34366928
Drug: CNS stimulants
Normalized name: CNS STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS stimulants (predominantly OROS-Methylphenidate, up to 54 mg per day)
Study: 34367149
Drug: Haploidentical stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haploidentical stem cell transplantation (haplo SCT) and dinutuximab (anti-GD2 antibody)
Study: 34367680
Drug: Canakinumab treatment
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab treatment for cytokine release syndrome (CRS) in COVID-19-induced pneumonia
Study: 34367728
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride (HDC) and low-dose interleukin-2 (IL-2)
Study: 34368242
Drug: Cardiac Shock
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Shock Wave Therapy
Study: 34369187
Drug: Inflammation defined
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflammation defined by hs-CRP level of ≥1.0 mg/L
Study: 34369333
Drug: CON (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (25 g whey protein hydrolysate)
Study: 34369333
Drug: LOW (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOW (25 g whey protein hydrolysate + 3179 mg Capolac®)
Study: 34369333
Drug: MED (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: MED (25 g whey protein hydrolysate + 6363 mg Capolac®)
Study: 34369333
Drug: HIGH (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH (25 g whey protein hydrolysate + 9547 mg Capolac®)
Study: 34369416
Drug: Cochlear implants
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implants (PTA ≥ 70 dB HL)
Study: 34369424
Drug: Depot medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot medroxyprogesterone acetate (MPA) 150-mg intramuscular injection
Study: 34369424
Drug: Efavirenz-based HIV
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz-based HIV therapy and rifampicin plus isoniazid
Study: 34369424
Drug: Depot MPA
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot MPA dosing frequency
Study: 34370076
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg BID with rosuvastatin 20 mg
Study: 34370076
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg BID with oral contraceptives
Study: 34370076
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (ethinylestradiol 30 µg + levonorgestrel 150 µg)
Study: 34370839
Drug: Anticancer drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticancer drugs (40 drugs significantly associated with diLQT)
Study: 34370839
Drug: Anticancer drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticancer drugs (9 drugs associated with VA without diLQT)
Study: 34370839
Drug: Kinase inhibitors
Normalized name: PROTEIN KINASE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinase inhibitors (20/49 drugs)
Study: 34370839
Drug: Hormonal therapies
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapies (4/49 drugs)
Study: 34370839
Drug: Immunotherapies (3/49
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapies (3/49 drugs)
Study: 34370839
Drug: Cytotoxics (12/49
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxics (12/49 drugs)
Study: 34370839
Drug: Miscellaneous (10/49
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miscellaneous (10/49 drugs)
Study: 34370839
Drug: Anticancer drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticancer drugs reporting
Study: 34370839
Drug: New signals
Approvals — FDA: no, EMA: no, PMDA: no
Description: New signals from drugs
Study: 34371366
Drug: quavonlimab 75
Normalized name: Quavonlimab
DrugBank: Quavonlimab (DB16422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: quavonlimab 75 mg Q6W plus pembrolizumab 200 mg Q3W
Study: 34373186
Drug: rabbit anti-thymocyte
Normalized name: Rabbit anti-thymocyte immunoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabbit anti-thymocyte globulin (ATG) 3 mg/kg on day 8 post-transplant
Study: 34373186
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ATG treatment)
Study: 34373952
Drug: Daily values
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily values or trends of clinical parameters associated with acute organ dysfunction, acid-base derangement, coagulation impairment, or systemic inflammation.
Study: 34374622
Drug: Global Evaluation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Global Evaluation of Treatment Effectiveness (GETE)
Study: 34374848
Drug: No supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplementation for patients with calcemia ≥ 2.16 mmol/l and PTH ≥ 1.9 pmol/l
Study: 34374848
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for patients with calcemia between 1.9 and 2.16 mmol/l and PTH > 4.7 pmol/l
Study: 34374848
Drug: Calcemia between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcemia between 1.9 and 2.16 mmol/l and PTH > 1.9 pmol/l
Study: 34374848
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of corrected calcemia and PTH on POD1
Study: 34375315
Drug: bNAb-derived CAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: bNAb-derived CAR T cell therapy
Study: 34375343
Drug: Universal testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal testing and treatment approach (HIV testing and ART initiation)
Study: 34375394
Drug: Balanced solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced solution (n=5522)
Study: 34375394
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (n=5530)
Study: 34376064
Drug: ESC 0/1h-hs-cTnT-algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESC 0/1h-hs-cTnT-algorithm with hs-cTnT change <7 ng/L
Study: 34376064
Drug: ESC 0/1h-hs-cTnT-algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESC 0/1h-hs-cTnT-algorithm with hs-cTnT change ≥7 ng/L
Study: 34376064
Drug: Novel derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel derived 0/3h-criteria for observe-zone patients with hs-cTnT concentration <15 ng/L and absolute change <4 ng/L
Study: 34376064
Drug: Novel derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel derived 0/3h-criteria with absolute change ≥6 ng/L
Study: 34376579
Drug: Isatuximab (CD38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatuximab (CD38 monoclonal antibody)
Study: 34376577
Drug: Itraconazole; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole; specific dosage and duration not mentioned
Study: 34377216
Drug: Routine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine daily stressors
Study: 34377592
Drug: Autologous EBV-expanded
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous EBV-expanded cytotoxic T lymphocytes (CTLs) in combination with gemcitabine and carboplatin chemotherapy
Study: 34379916
Drug: CIS43LS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIS43LS (5 mg/kg, 20 mg/kg, 40 mg/kg)
Study: 34379916
Drug: CIS43LS (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIS43LS (40 mg/kg)
Study: 34380536
Drug: Iguratimod (IGU)
Normalized name: dextromethorphan
DrugBank: Iguratimod (DB12233)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Iguratimod (IGU) as induction therapy for 24 weeks
Study: 34380536
Drug: Iguratimod (IGU)
Normalized name: dextromethorphan
DrugBank: Iguratimod (DB12233)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Iguratimod (IGU) as maintenance therapy for 24 weeks
Study: 34380536
Drug: Cyclophosphamide as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide as induction therapy for 24 weeks
Study: 34380536
Drug: Azathioprine as
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine as maintenance therapy for 24 weeks
Study: 34380625
Drug: CCW702 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCW702 (a bispecific antibody)
Study: 34380662
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks until disease progression/unacceptable toxicity
Study: 34380663
Drug: Ipilimumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks)
Study: 34380979
Drug: 3HP treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3HP treatment (rifapentine plus isoniazid) delivered by RN/CHW program
Study: 34380979
Drug: 3HP treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3HP treatment
Study: 34381382
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT), details on dosage and duration not available
Study: 34382075
Drug: Endometrial progesterone
Normalized name: progesterone Vaginal Insert [Endometrin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial progesterone (P4) levels and 17α-hydroxyprogesterone levels measured after 5 days of vaginal treatment with micronised progesterone (400 mg/12 h) and oestradiol valerate (6 mg/day).
Study: 34382365
Drug: pegargiminase (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegargiminase (36 mg/m) plus pemetrexed and cisplatin (ADIPemCis)
Study: 34383370
Drug: Sorafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (150 mg/m² continuous oral twice daily) with Irinotecan (oral, once daily days 1-5, every 21 days)
Study: 34383370
Drug: Sorafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (150 mg/m²)
Study: 34383393
Drug: Electroconvulsive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive Therapy
Study: 34383662
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (cognitive games on tablet computers and cycling on the ergometer sequentially on a non-VR platform)
Study: 34383676
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (control group).
Study: 34383682
Drug: Weekly patient-reported
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly patient-reported outcomes using Brief Psychiatric Rating Scale, Calgary Depression Scale, and Positive and Negative Syndrome Scale.
Study: 34384079
Drug: 2 consecutive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 consecutive intracavernous injections of allogeneic Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs)
Study: 34384227
Drug: Multimodal Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal Treatment Study of ADHD (MTA)
Study: 34384460
Drug: Elevated suPAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated suPAR above 3 ng/ml
Study: 34384460
Drug: Elevated suPAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated suPAR above 9 ng/ml
Study: 34384490
Drug: Baseline procedures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline procedures including neurological and neuropsychological examinations; tau and amyloid positron emission tomography; magnetic resonance imaging and spectroscopy; lumbar puncture; blood and saliva collection; standardized self-report measures of neuropsychiatric, cognitive, and daily functioning.
Study: 34385584
Drug: ZEN-3694 combined
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZEN-3694 combined with CDK4/6 inhibitors
Study: 34385584
Drug: ZEN-3694 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZEN-3694 treatment
Study: 34385708
Drug: Tumor-infiltrating lymphocytes
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor-infiltrating lymphocytes (TILs) administered with nivolumab
Study: 34385708
Drug: TIL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIL treatment
Study: 34386974
Drug: Thrombopoietin-receptor agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombopoietin-receptor agonists (TPO-RAs)
Study: 34387119
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) therapy, 2 times a week for 6 weeks (total of 12 treatments)
Study: 34387310
Drug: SARS-CoV-2 polymerase
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 polymerase chain reaction, immunoglobulin G (IgG) testing for 6 months
Study: 34387310
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies detection
Study: 34387570
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (bedside irrigation, primary closure, antibiotics, discharge with follow-up)
Study: 34387570
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (surgical debridement, irrigation, and closure)
Study: 34387648
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA COVID-19 vaccine (2 doses, 21 days apart)
Study: 34387648
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA COVID-19 vaccine (in patients with B-NHL)
Study: 34387648
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA COVID-19 vaccine (in patients with i-B-NHL vs a-B-NHL)
Study: 34387679
Drug: Cannabidiol, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol, 300 mg (150 mg twice per day) plus standard care
Study: 34388386
Drug: Talazoparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (1 mg per day; or 0.75 mg per day in patients with moderate renal impairment)
Study: 34388972
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) ß-1a, 3 doses of 125 μg by subcutaneous administration (days 1, 6, and 11)
Study: 34389237
Drug: Novel osimertinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel osimertinib combination therapies (Group A)
Study: 34389237
Drug: Non-biomarker selected
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-biomarker selected therapies (chemotherapy- or EGFR-TKI-based) (Group B)
Study: 34389237
Drug: Local practice
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local practice treatment (Group C)
Study: 34389568
Drug: Metabolic bariatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic bariatric surgery (MBS), specifically vertical sleeve gastrectomy (VSG), details on dosage and duration not available.
Study: 34389568
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment approaches including lifestyle change, metformin, thiazolidinediones, or insulin, details on dosage and duration not available.
Study: 34957480
Drug: Intramuscular plasmid
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular plasmid treatment
Study: 34957480
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of plasmid
Study: 34389618
Drug: GWN323 (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWN323 (1500 mg every 3 weeks)
Study: 34389618
Drug: GWN323 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWN323 (750 mg) + spartalizumab (300 mg every 3 weeks)
Study: 34389618
Drug: GWN323 (single-agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWN323 (single-agent)
Study: 34389618
Drug: GWN323 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWN323 + spartalizumab (combination)
Study: 34389694
Drug: 5-fluorouracil (5FU)-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5FU)-based adjuvant chemotherapy
Study: 34389930
Drug: Insulin pumps
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin pumps and CGM